A systematic review and meta-analysis of randomized controlled trials with antimuscarinic drugs for overactive bladder. - Wikidata - wikimedia - TriplyDB

A systematic review and meta-analysis of randomized controlled trials with antimuscarinic drugs for overactive bladder.

A systematic review and meta-analysis of randomized controlled trials with antimuscarinic drugs for overactive bladder.

http://www.wikidata.org/entity/Q34594344

about

Which anticholinergic drug for overactive bladder symptoms in adults An update on the use of transdermal oxybutynin in the management of overactive bladder disorder Overactive bladder Overactive bladder syndrome: Current pathophysiological concepts and therapeutic approaches Adverse event assessment of antimuscarinics for treating overactive bladder: a network meta-analytic approach Inhaled anticholinergic drugs and risk of acute urinary retention.A review of prospective Clinical Trials for neurogenic bladder: Pharmaceuticals.Efficacy and safety of ginger-salt-indirect moxibustion for urge urinary incontinence after stroke: protocol for a pilot multicentre randomised controlled trial.Tolterodine extended release in the treatment of male OAB/storage LUTS: a systematic review.Tolterodine extended-release for overactive bladder.An overview of the clinical use of antimuscarinics in the treatment of overactive bladder Bladder dysfunction in diabetes mellitus.Postmenopausal overactive bladder Korean version of the overactive bladder symptom score questionnaire: translation and linguistic validation.Duration of Antimuscarinic Administration for Treatment of Overactive Bladder Before Which One Can Assess Efficacy: An Analysis of Predictive Factors.Overactive bladder, differential diagnosis, and clinical utility of fesoterodine New developments in the management of overactive bladder: focus on mirabegron and onabotulinumtoxinA.Overactive bladder - 18 years - Part II Knowledge and understanding of urinary incontinence: survey of family practitioners in northern Alberta.A phase II dose-ranging study of mirabegron in patients with overactive bladder Update on tolterodine extended-release for treatment of overactive bladder Rationale for the use of anticholinergic agents in overactive bladder with regard to central nervous system and cardiovascular system side effects.Basic mechanisms of urgency: roles and benefits of pharmacotherapy Evaluating Outcomes in Patients with Overactive Bladder within an Integrated Healthcare Delivery System Using a Treatment Patterns Analyzer Randomized trial - oxybutynin for treatment of persistent plantar hyperhidrosis in women after sympathectomy.The attitudes of Urologists and Gynecologists about overactive bladder and treatment of it in Turkey: A questionnaire survey.Rehabilitation in practice: neurogenic lower urinary tract dysfunction and its management.The medical treatment of overactive bladder, including current and future treatments.An overview on mixed action drugs for the treatment of overactive bladder and detrusor overactivity.Management of mixed urinary incontinence.β3-receptor agonists for overactive bladder--new frontier or more of the same?Mirabegron: β3-adrenergic receptor agonist for the treatment of overactive bladder.Understanding clinic options for overactive bladder.New therapies in the treatment of overactive bladder.Solifenacin: pharmacology and clinical efficacy.New agents to treat lower urinary tract and pelvic floor disorders Critical analysis of phase II and III randomised control trials (RCTs) evaluating efficacy and tolerability of a β₃-adrenoceptor agonist (Mirabegron) for overactive bladder (OAB).Phase II drugs that target cholinergic receptors for the treatment of overactive bladder.Solabegron: a potential future addition to the β-3 adrenoceptor agonist armamentarium for the management of overactive bladder.Diabetic cystopathy: A review.

P2860

Q24203880-9FDD8F64-CDCC-4A99-9CFA-64523CD63BCE Q26749105-2F260617-4DAF-4774-853C-6A7EC034EBF1 Q26766174-ED5A4F48-E149-4F50-8A43-00AEE47A8977 Q27022279-CF9BBD6A-462A-47CD-9A5D-F151D5BFCF65 Q28742444-63A6642F-63A5-4CEA-B9F9-4AFC2F5236E6 Q34024144-F1AFB611-D49F-4C8A-AD66-FF547DAC1324 Q34195032-BD280579-D03E-418F-BA32-06C1341F07D1 Q34397227-8FE546C5-5F37-4DD0-B333-E3D4328255CE Q34502903-9CCE9AB4-1254-4FD8-9958-14BE9E19D277 Q34610640-54EAEBD2-A033-4E00-93D3-1C6789A3FD03 Q35042575-D7C533B2-E8DA-4E31-A9FF-37C43494E40D Q35155238-92FACA5F-66B5-4999-9D23-7B72831A1B92 Q35157329-3A739FB5-22C6-4E6D-8580-3D93DA2E4CAC Q35539612-97784BF0-97A8-4DF3-8CE4-E0D8A1A1E69D Q36090770-07F06E31-AB81-4D73-8F83-3668E847729E Q36429651-43586207-5890-4F42-B964-0A6B2EFA427F Q36789948-3A1A79D0-7ADE-47E9-98A7-0E630F6A38C8 Q36912766-7A2611F4-BEB3-4706-9F72-D58495185C49 Q37008174-AE4CA072-6362-4018-8E1B-919C4609B402 Q37100337-2287B484-D84E-4370-95B8-10433ED8B3CF Q37283585-B1EA9C03-984D-426E-AB66-EB3065C824EF Q37399563-5F65638E-E925-4946-BE0C-8C4ABB79DC41 Q37428717-05B8293A-9830-4AA8-A51A-4B95D16CBEBC Q37441427-AD985230-9AD4-4FAB-9A78-D9CBA877A225 Q37549915-AC57C662-5467-4B3F-B746-1416772898F0 Q37671608-07D24F3C-7554-425C-A16B-F1FD5609F9B9 Q37768289-885E8E37-633F-4284-8E2A-67F96AF1B641 Q37836943-75B360E8-5BC3-4493-B2C9-0022B3FFE94E Q38024986-B0E61AD6-C652-4F57-9FBF-4B4CEBC25A84 Q38039168-96735361-288B-4A3D-BFF6-DE63C521049E Q38107167-8CF306AB-C4CB-4B18-BD9A-F2549EAE34B8 Q38113772-B3A21E48-96E6-4BEE-B43F-C6963458EA04 Q38118177-B01440B4-E50D-4E6A-BCC5-3B6B3DEAAB20 Q38124045-C9D65E82-8F7F-4C0F-86CF-B8F275428465 Q38177369-2328586C-4033-429B-9605-F2B8625265E8 Q38187656-4A7B647C-704B-4924-9114-FE4ABB4C1C46 Q38193896-0BA6AE36-7516-4552-906C-D010DDDF415A Q38217760-71243115-5B12-416A-A002-349F837F59EF Q38306806-1B5EDCE7-B130-4F51-9168-A7ABDD590690 Q38331443-6FA15F9C-E98F-43F4-924D-8F1AF1EFE213

P2860

A systematic review and meta-analysis of randomized controlled trials with antimuscarinic drugs for overactive bladder.

http://www.wikidata.org/entity/Q34594344

description

2008 nî lūn-bûn

@nan

2008 թուականի Յուլիսին հրատարակուած գիտական յօդուած

@hyw

2008 թվականի հուլիսին հրատարակված գիտական հոդված

@hy

2008年の論文

@ja

2008年論文

@yue

2008年論文

@zh-hant

2008年論文

@zh-hk

2008年論文

@zh-mo

2008年論文

@zh-tw

2008年论文

@wuu

name

A systematic review and meta-a ...... drugs for overactive bladder.

@ast

A systematic review and meta-a ...... drugs for overactive bladder.

@en

A systematic review and meta-a ...... drugs for overactive bladder.

@nl

type

label

A systematic review and meta-a ...... drugs for overactive bladder.

@ast

A systematic review and meta-a ...... drugs for overactive bladder.

@en

A systematic review and meta-a ...... drugs for overactive bladder.

@nl

prefLabel

A systematic review and meta-a ...... drugs for overactive bladder.

@ast

A systematic review and meta-a ...... drugs for overactive bladder.

@en

A systematic review and meta-a ...... drugs for overactive bladder.

@nl

P1433

Q34594344-DDEAE231-B5F5-4AE1-9AF8-8C27C2FF4A4A

P1476

Q34594344-DCA40261-BD1C-45FB-B150-0B99C0100BBF

P2093

Q34594344-5A654C9F-6EC3-4D8A-A270-3A1989AFC483

Q34594344-737D4252-7B6D-48E3-943E-947D9640C1A2

Q34594344-A1F717D1-60A1-42D4-BE9A-524999F1F2B1

Q34594344-ABEB4CD5-57C3-4DC4-8692-594519BBB8EA

Q34594344-B756CA24-F923-4FD8-9737-5870C334FF4F

Q34594344-D2B319D3-0DEB-4BDF-8FA4-CFAD78EC02FD

Q34594344-E30940DC-8F5F-401B-936D-3C126D455BA5

P304

Q34594344-31C47196-C1EE-4311-A94A-C6AC8ACA92D8

P31

Q34594344-F0D47ADC-D7BA-40C9-8944-D32B187C483D

Q34594344-dcf5ba1f-cce3-45f1-9fb7-934e1bf02836

P356

Q34594344-674B6049-0BCD-409C-8084-4A80C521784F

P407

Q34594344-1457BDC1-61BB-418C-8FFB-3C51B89835DE

P433

Q34594344-0034F1E6-5672-44C2-B18F-89A6C44924B7

P478

Q34594344-FBA4E0E9-D087-4BB3-8BC2-E80B155712E6

P577

Q34594344-E5C41037-5024-450A-8E78-B11B676E6425

P5875

Q34594344-67ADAD1F-16D7-486D-9986-9581153CF986

P698

Q34594344-EEDDF1A7-DD17-4CFF-8604-93A86A3A7739

P921

Q34594344-97E24A4E-DC6E-401D-99D5-FA08411F5DDE

P356

J.EURURO.2008.06.080

P1433

European Urology

P1476

A systematic review and meta-a ...... drugs for overactive bladder.

@en

P2093

Antonio Galfano

http://www.w3.org/2001/XMLSchema#string

Carolina D'Elia

http://www.w3.org/2001/XMLSchema#string

Giacomo Novara

http://www.w3.org/2001/XMLSchema#string

Silvia Secco

http://www.w3.org/2001/XMLSchema#string

Stefano Cavalleri

http://www.w3.org/2001/XMLSchema#string

Vincenzo Ficarra

http://www.w3.org/2001/XMLSchema#string

Walter Artibani

http://www.w3.org/2001/XMLSchema#string

P304

740-763

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1016/J.EURURO.2008.06.080

http://www.w3.org/2001/XMLSchema#string

P407

P433

4

http://www.w3.org/2001/XMLSchema#string

P478

54

http://www.w3.org/2001/XMLSchema#string

P577

2008-07-09T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

51406793

http://www.w3.org/2001/XMLSchema#string

P698

18632201

http://www.w3.org/2001/XMLSchema#string

P921